Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which MRI dye gives the best picture of heart damage?

NCT ID NCT03057561

Diagnosis Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two contrast agents (Dotarem and Gadovist) used in cardiac MRI to see which provides clearer images of heart muscle damage. 120 adults with coronary artery disease or cardiomyopathy received one of the two dyes during their scan. Researchers rated image quality and tracked heart-related outcomes over time to see if one agent was better at linking scan findings to real-world health events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Gadolinium-based contrast agents (Dotarem and Gadovist)
What this could lead to
If one contrast agent proves superior, it could improve heart MRI accuracy and help doctors better predict heart-related events.
What could go wrong
This is a small pilot study (120 people) comparing two already-approved agents, so major breakthroughs are unlikely. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Oct 2016

Finished

Jun 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing clinically referred CMR. Exclusion Criteria: 1. Patients who are unable to give informed consent. 2. Individuals with severe claustrophobia. 3. Individuals unable to lie flat for 90 minutes (the anticipated amount of time to complete the MRI procedure). 4. Individuals who are pregnant. 5. Patients with implants or pacemakers. 6. Patients that have hypersensitivity to components of gadolinium. 7. Patients with renal failure. 8. Patients who had any trauma or surgery which may have left ferromagnetic material in the body.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiomyopathy coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiomyopathy Coronary artery disease

More trials for these conditions

Other studies related to the condition(s) this trial covers.